Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Res. 2020 Oct 19;19(2):215–222. doi: 10.1158/1541-7786.MCR-20-0434

Figure 4.

Figure 4.

BAP1 loss sensitizes uveal melanoma cells to quisinostat in vivo. A, Time course of tumor growth in a mouse intrascapular fat pad xenograft model using BAP1-mutant MM28 and MP46 and BAP1-wildtype MP41 uveal melanoma cells treated with quisinostat versus DMSO vehicle control. B, Final weight at necropsy of tumors treated with quisinostat versus control. C, Representative examples of tumors treated with quisinostat versus vehicle control at necropsy. Q, quisinostat; V, vehicle. P values: *** < 0.0005, ** < 0.005, * < 0.05.